{{Rsnum
|rsid=4673727
|Chromosome=2
|position=200130964
|Orientation=plus
|GMAF=0.1455
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 9.0 | 91.0
| HCB | 0.0 | 41.9 | 58.1
| JPT | 1.8 | 28.8 | 69.4
| YRI | 2.8 | 34.8 | 62.4
| ASW | 3.6 | 19.6 | 76.8
| CHB | 0.0 | 41.9 | 58.1
| CHD | 4.7 | 29.2 | 66.0
| GIH | 1.0 | 12.9 | 86.1
| LWK | 0.0 | 0.0 | 0.0
| MEX | 14.0 | 28.1 | 57.9
| MKK | 0.0 | 21.9 | 78.1
| TSI | 2.0 | 7.9 | 90.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4673727
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.10, combined P value= 1.10E-06.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470152
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4673727
|overall_frequency_n=104
|overall_frequency_d=128
|overall_frequency=0.8125
|n_genomes=55
|n_genomes_annotated=0
|n_haplomes=94
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}